Meissner et al. developed radiomics classifers allows for a non-invasive assessment of the intracranial PD-L1 expression in patients with brain metastases (BM) secondary to NSCLC with AUC of 0.84 (Meissner et al., 2023). This evidence concerns the gene CD274 and non-small cell lung carcinoma.